2-Formylamino-2-deoxy-D-galactose | 37085-24-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Formylamino-2-deoxy-D-galactose
• 英文别名: N-[(2R,3R,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]formamide
• CAS: 37085-24-8
• 化学式: C₇H₁₃NO₆
• 分子量: 207.183
• InChiKey: VUEJMPOYVSFTMJ-WNJXEPBRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甲酸对硝基苯酯 、 2-氨基-2-脱氧-D-半乳糖盐酸盐 生成 2-Formylamino-2-deoxy-D-galactose
  参考文献：
  名称：

  p-Nitrophenyl Formate as a Reagent for PreparingN-Formyl-hexosamines

  摘要：

  DOI：

  10.1246/bcsj.45.1253

文献信息

• Compositions for Targeted Delivery of siRNA
  申请人：Rozema David B.

  公开号：US20110207799A1

  公开（公告）日：2011-08-25

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内肝细胞的组合物。靶向RNAi多核苷酸与共靶向递送聚合物一起给予。递送聚合物提供膜穿透功能，用于将RNAi多核苷酸从细胞外运送到细胞内。可逆修饰为递送聚合物提供生理响应性。
• GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
  申请人：Hadwiger Philipp

  公开号：US20120157509A1

  公开（公告）日：2012-06-21

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内细胞的组合物。与单独的靶向配体相比，药代动力学调节剂改善了体内靶向。靶向配体-药代动力学调节剂靶向基团靶向的RNAi多核苷酸可以单独或与共靶向递送聚合物一起在体内给予。
• [EN] DISUBSTITUTED MALEIC ANHYDRIDES WITH ALTERED KINETICS OF RING CLOSURE<br/>[FR] ANHYDRIDES MALÉIQUES DISUBSTITUÉS AYANT UNE CINÉTIQUE MODIFIÉ DE FERMETURE DE CYCLE
  申请人：ARROWHEAD MADISON INC

  公开号：WO2012173784A1

  公开（公告）日：2012-12-20

  We describe anhydride compounds suitable for physiologically labile modification of amine- containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.

  我们描述了适用于生理易降解修饰胺基含有分子的酐化合物。所述的酐形成可逆连接，具有适合体内传递生物活性分子的理想动力学特性。还描述了通过修饰膜活性多胺与所述酐化合物形成的内体溶解聚合物。
• In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages
  申请人：Rozema David B.

  公开号：US20120172412A1

  公开（公告）日：2012-07-05

  The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

  本发明涉及用于将RNA干扰（RNAi）多核苷酸传递至体内细胞的组合物。这些组合物包括与酶可切割二肽-酰胺基苄-碳酸酯掩蔽剂可逆修饰的两性膜活性多胺。修饰掩蔽了聚合物的膜活性，而可逆性提供了生理响应性。可逆修饰的多胺（动态多共轭物或DPC）进一步与RNAi多核苷酸共价连接，或与靶向RNAi多核苷酸的分子结合物共同给药。
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2019075357A1

  公开（公告）日：2019-04-18

  Among other things, the present disclosure provides technologies for altering splicing, particularly for increasing inclusion of exons in splicing products. In some embodiments, the present disclosure provides SMN2 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides chirally controlled SMN2 oligonucleotide compositions. In some embodiments, provided oligonucleotides and compositions can increase level of an exon 7-containing SMN2 splicing product and/or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of splicing-related conditions, disorders and diseases. In some embodiments, the present disclosure provides methods for treating SMN2-related conditions, disorders and diseases such as SMA (spinal muscular atrophy) and ALS (amyotrophic lateral sclerosis).

  本公开提供了用于改变剪接的技术，特别是用于增加剪接产物中外显子包含量的技术。在某些实施例中，本公开提供了SMN2寡核苷酸、组合物及其方法。在某些实施例中，本公开提供了立体控制的SMN2寡核苷酸组合物。在某些实施例中，所提供的寡核苷酸和组合物可以增加外显子7包含的SMN2剪接产物的水平和/或其基因产物的水平。在某些实施例中，本公开提供了用于治疗剪接相关疾病、疾病和疾病的方法。在某些实施例中，本公开提供了用于治疗SMN2相关疾病、疾病和疾病的方法，如脊髓性肌萎缩症（SMA）和肌萎缩侧索硬化（ALS）。